Replimune Group Inc (REPL)

Nov 11, 2026

Replimune Group (REPL) saw its short interest rise to 36.13% of the float as of October 30th, an increase of 6.23% from October 15th, according to new data from Benzinga. It would take an estimated 8.31 days for short sellers to cover their positions at current trading volumes. The article also details recent hedge fund activity, with 117 institutions adding and 120 decreasing shares, and highlights insider selling activity totaling 14 sales and no purchases in the last 6 months.

Nov 7, 2026

This report provides a technical analysis of Replimune Group Inc. (NASDAQ: REPL), highlighting strong sentiment across all horizons supporting an overweight bias. It outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal analysis, identifying support and resistance levels for near-term, mid-term, and long-term horizons.

Nov 4, 2026

Jim Cramer endorsed buying FedEx Freight Holding Company (NYSE: FDXF) on CNBC's "Mad Money Lightning Round," citing its strong recovery and better-than-expected third-quarter financial results. He also provided recommendations on other stocks, suggesting Replimune Group (NASDAQ: REPL) as a speculative play, advising sticking with Tesla for self-driving exposure over Aurora Innovation, and highlighting Celestica Inc. (NYSE: CLS) as a solid company likely to bounce first. Cramer also mentioned that the upcoming election would be a "clearing event" for Sterling Infrastructure (NASDAQ: STRL).

Oct 28, 2026

Replimune Group (NASDAQ: REPL) reported a fiscal second-quarter loss of $0.54 per share, beating consensus estimates, with a net loss that narrowed to $57.1 million from $83.1 million year over year. The company recorded no revenue as its oncolytic therapy, TUDRIQEV, launched after the quarter closed. While the early launch indicators are encouraging in terms of account adoption and payer coverage, the market is awaiting revenue guidance and patient disclosure to fully credit the launch.